Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 28, 2026, 12:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Fluoxetine Capsules 40 mg Clear all

Conditions: Covid19
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Healthy
Interventions: Fluoxetine Capsules 40 mg, Prozac Pulvules 40 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,944 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 93
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more

Conditions: Major Depressive Disorder
Interventions: Placebo, Levomilnacipran, Fluoxetine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 48
States / cities: Dothan, Alabama • Tucson, Arizona • Anaheim, California + 40 more

Conditions: Major Depressive Disorder
Interventions: Placebo, fluoxetine, duloxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 44
States / cities: Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 41 more

Conditions: Social Phobia
Interventions: Social Effectiveness Therapy for Children (SET-C), Fluoxetine, Pill Placebo; Behavioral · Drug
Lead sponsor: University of Central Florida; Other
Eligibility: 8 Years to 16 Years
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: University of Maryland, College Park, Maryland

Conditions: Bipolar Disorder
Interventions: Standard of Care, Ketamine, D-cycloserine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: Levomilnacipran ER, Fluoxetine, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 51
States / cities: Little Rock, Arkansas • Beverly Hills, California • Corona, California + 45 more

Conditions: Healthy
Interventions: fluoxetine HCL 40 mg capsules; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Depression, Palliative Care, Cancer, Mental Disorder
Interventions: Methylphenidate, Placebo, Selective Serotonin Uptake Inhibitor (SSRI); Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Depressive Disorder, Major
Interventions: JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more

Conditions: Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions: Valbenazine Oral Capsule; Drug
Lead sponsor: Stephen Ruedrich; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Major Depressive Disorder
Interventions: Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more

Conditions: Major Depressive Disorder
Interventions: duloxetine, Placebo, fluoxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 24
States / cities: Costa Mesa, California • Irvine, California • Palo Alto, California + 21 more

Search by objective public record fields.

Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)

Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mg

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Treatment of Childhood Social Phobia

NMDA Antagonists in Bipolar Depression

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder

Bioequivalence Study of Fluoxetine HCL 40 mg Capsules Under Fasting Conditions

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder